CHFR and gastric cancer: In a small study of 12 patients with advanced stage gastric cancer that received adjuvant paclitaxel, CHFR promoter CpG island methylation was associated with a better clinical response compared to cancers with unmethylated CHFR of which the majority showed progressive disease [57].